Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATG-300
- Development stage
- Preclinical
- Lead developer
- Ategenos Pharmaceuticals
- Modality
- Peptides
- Administration
- Transdermal
01
Overview
ATG-300 is an investigational transdermal drug delivery system developed by Ategenos Pharmaceuticals, designed to deliver a glucagon-like peptide-1 (GLP-1) receptor agonist. The system utilizes Ategenos's proprietary SmartPatch technology, which combines a transdermal patch with integrated electronics for real-time adherence monitoring. By delivering the GLP-1 agonist through the skin, ATG-300 aims to provide a non-invasive, sustained-release alternative to traditional subcutaneous injections, potentially improving patient compliance and therapeutic consistency in the management of metabolic conditions such as obesity and type 2 diabetes.
02
Targets
Beyond the preview
Go deeper on ATG-300.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATG-300.